Mallinckrodt Stock Forecast, Price & News

Mallinckrodt (NYSE:MNK) Frequently Asked Questions

What stocks does MarketBeat like better than Mallinckrodt?

Wall Street analysts have given Mallinckrodt a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Mallinckrodt wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Mallinckrodt's earnings last quarter?

Mallinckrodt plc (NYSE:MNK) posted its quarterly earnings results on Tuesday, August, 4th. The company reported $1.89 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.55. The company earned $700.90 million during the quarter, compared to analysts' expectations of $630.19 million. Mallinckrodt had a positive trailing twelve-month return on equity of 34.26% and a negative net margin of 89.94%. Mallinckrodt's revenue was down 14.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.53 EPS.
View Mallinckrodt's earnings history.

Who are Mallinckrodt's key executives?

Mallinckrodt's management team includes the following people:

• Mark C. Trudeau, President, Chief Executive Officer & Director
• Bryan M. Reasons, Chief Financial Officer & Executive Vice President
• Steven Joseph Romano, Chief Scientific Officer & Executive VP
• Babatunde Adekunle Otulana, Chief Medical Officer & Senior Vice President
• Michele Robertson, Chief Compliance Officer & Senior Vice President

Who are some of Mallinckrodt's key competitors?

Some companies that are related to Mallinckrodt include Celyad Oncology (CYAD), Regulus Therapeutics (RGLS), Synthetic Biologics (SYN), Monopar Therapeutics (MNPR), RenovoRx (RNXT), ABVC BioPharma (ABVC), NanoViricides (NNVC), Rockwell Medical (RMTI), Cellectar Biosciences (CLRB), Merrimack Pharmaceuticals (MACK), Reviva Pharmaceuticals (RVPH), Synaptogenix (SNPX), Lotus Pharmaceuticals (LTUS), FSD Pharma (HUGE) and Acasti Pharma (ACST).
View all of MNK's competitors.

What other stocks do shareholders of Mallinckrodt own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mallinckrodt investors own include Gilead Sciences (GILD), Micron Technology (MU), Bausch Health Companies (BHC), Endo International (ENDP), Teva Pharmaceutical Industries (TEVA), Gerdau (GGB), AT&T (T), Alibaba Group (BABA), (CELG) and Advanced Micro Devices (AMD).

What is Mallinckrodt's stock symbol?

Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

What is Mallinckrodt's stock price today?

One share of MNK stock can currently be purchased for approximately $0.20.

How much money does Mallinckrodt make?

Mallinckrodt has a market capitalization of $16.54 million and generates $3.16 billion in revenue each year. The company earns $-996,500,000.00 in net income (profit) each year or $8.88 on an earnings per share basis.

How many employees does Mallinckrodt have?

Mallinckrodt employs 3,400 workers across the globe.

What is Mallinckrodt's official website?

The official website for Mallinckrodt is www.mallinckrodt.com.

Where are Mallinckrodt's headquarters?

Mallinckrodt is headquartered at COLLEGE BUSINESS & TECHNOLOGY PARK CRUISERATH BLANCHARDSTOWN, DUBLIN 15 L2, D15.

How can I contact Mallinckrodt?

Mallinckrodt's mailing address is COLLEGE BUSINESS & TECHNOLOGY PARK CRUISERATH BLANCHARDSTOWN, DUBLIN 15 L2, D15. The company can be reached via phone at (531) 696-0000 or via email at [email protected].